These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2002511)

  • 1. Development and utilization of physiologically based pharmacokinetic models for toxicological applications.
    Leung HW
    J Toxicol Environ Health; 1991 Mar; 32(3):247-67. PubMed ID: 2002511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances.
    Leung HW; Paustenbach DJ
    Toxicol Lett; 1995 Sep; 79(1-3):55-65. PubMed ID: 7570674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of physiologically based pharmacokinetic models to establish biological exposure indexes.
    Leung HW
    Am Ind Hyg Assoc J; 1992 Jun; 53(6):369-74. PubMed ID: 1605109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the tissue residue approach in ecological risk assessment.
    Sappington KG; Bridges TS; Bradbury SP; Erickson RJ; Hendriks AJ; Lanno RP; Meador JP; Mount DR; Salazar MH; Spry DJ
    Integr Environ Assess Manag; 2011 Jan; 7(1):116-40. PubMed ID: 21184572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model.
    Andersen ME; MacNaughton MG; Clewell HJ; Paustenbach DJ
    Am Ind Hyg Assoc J; 1987 Apr; 48(4):335-43. PubMed ID: 3591649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment.
    Andersen ME
    Cell Biol Toxicol; 1989 Dec; 5(4):405-15. PubMed ID: 2627676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modeling of nanoparticles.
    Li M; Al-Jamal KT; Kostarelos K; Reineke J
    ACS Nano; 2010 Nov; 4(11):6303-17. PubMed ID: 20945925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
    Pelekis M; Gephart LA; Lerman SE
    Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New mathematical methods in pharmacokinetic modeling.
    Durisová M; Dedík L
    Basic Clin Pharmacol Toxicol; 2005 May; 96(5):335-42. PubMed ID: 15853925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in pharmacokinetic modeling.
    Ahmad AM
    Biopharm Drug Dispos; 2007 Apr; 28(3):135-43. PubMed ID: 17295411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of physiologically based pharmacokinetic models for use in risk assessment.
    Chiu WA; Barton HA; DeWoskin RS; Schlosser P; Thompson CM; Sonawane B; Lipscomb JC; Krishnan K
    J Appl Toxicol; 2007; 27(3):218-37. PubMed ID: 17299829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
    Clewell RA; Clewell HJ
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):129-43. PubMed ID: 18077066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps.
    Loizou G; Spendiff M; Barton HA; Bessems J; Bois FY; d'Yvoire MB; Buist H; Clewell HJ; Meek B; Gundert-Remy U; Goerlitz G; Schmitt W
    Regul Toxicol Pharmacol; 2008 Apr; 50(3):400-11. PubMed ID: 18331772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting maternal rat and pup exposures: how different are they?
    Yoon M; Barton HA
    Toxicol Sci; 2008 Mar; 102(1):15-32. PubMed ID: 18024990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.